NEW YORK (Reuters) - Bristol-Myers Squibb Co, which sells leading blood clot preventer Plavix, on Thursday dismissed Eli Lilly and Co’s rival Effient drug as a “niche” product that has harmed or failed to help three groups of patients in a big study. Effient, which is awaiting approval by U.S. regulators, has been widely touted as a medicine that could supplant the $5 billion-a-year Plavix as the standard treatment to prevent heart attacks among heart patients, including those receiving stents.
